872366-74-0 = 872365-14-5 反应条件:1.1 Reagents: Sodium Hydroxide Solvents: Water; 4 H,50 °C1.2 Reagents: Sulfuric Acid Solvents: Water; Ph 9 - 10 标题:Using A Johnson-Claisen Rearrangement Strategy To Construct Azaindoles - A Streamlined And Concise Route For The Commercial Process Of Fevipiprant 作者:Mathes,Christian; Et Al 参考文献:European Journal Of Organic Chemistry 日期:2021 卷标:2021(31) 页码:4490-4494]
1638892-78-0 = 872365-14-5 反应条件:1.1 Reagents: Potassium Carbonate,Triphenylphosphine Catalysts: Palladium Diacetate,Cuprous Iodide Solvents: Ethanol,Toluene; Rt -> 75 °C; 12 H,75 °C2.1 Catalysts: Pivalic Acid,N-Acetyl-L-Cysteine Solvents: Methyl Isobutyl Ketone; 4 H,155 °C2.2 Catalysts: Pivalic Acid Solvents: Methyl Isobutyl Ketone; 15 H,1.1 - 1.5 Bar,145 °C2.3 Reagents: Sodium Hydroxide Solvents: Water; 4 H,50 °C2.4 Reagents: Sulfuric Acid Solvents: Water; Ph 9 - 10 标题:Using A Johnson-Claisen Rearrangement Strategy To Construct Azaindoles - A Streamlined And Concise Route For The Commercial Process Of Fevipiprant 作者:Mathes,Christian; Et Al 参考文献:European Journal Of Organic Chemistry 日期:2021 卷标:2021(31) 页码:4490-4494]
872366-74-0 = 872365-14-5 反应条件:1.1 Reagents: Sodium Hydroxide,Methyl 2-Methyl-7-[[4-(Methylsulfonyl)-2-(Trifluoromethyl)Phenyl]Methyl]-7H-Pyrr... Solvents: Acetone,Water; Overnight,Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; Ph 3,Rt 标题:Discovery Of Fevipiprant (Nvp-Qaw039),A Potent And Selective Dp2 Receptor Antagonist For Treatment Of Asthma 作者:Sandham,David A.; Et Al 参考文献:Acs Medicinal Chemistry Letters 日期:2017 卷标:8(5) 页码:582-586]
1445-45-0 + 2092997-91-4 = 872365-14-5 反应条件:1.1 Catalysts: Pivalic Acid,N-Acetyl-L-Cysteine Solvents: Methyl Isobutyl Ketone; 4 H,155 °C1.2 Catalysts: Pivalic Acid Solvents: Methyl Isobutyl Ketone; 15 H,1.1 - 1.5 Bar,145 °C1.3 Reagents: Sodium Hydroxide Solvents: Water; 4 H,50 °C1.4 Reagents: Sulfuric Acid Solvents: Water; Ph 9 - 10 标题:Using A Johnson-Claisen Rearrangement Strategy To Construct Azaindoles - A Streamlined And Concise Route For The Commercial Process Of Fevipiprant 作者:Mathes,Christian; Et Al 参考文献:European Journal Of Organic Chemistry 日期:2021 卷标:2021(31) 页码:4490-4494]
1: White C, Wright A, Brightling C. Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207. doi: 10.1080/13543784.2018.1432592. Epub 2018 Jan 30. 14(5):e24641. doi: 10.7759/cureus.24641. 3: Kao CC, Parulekar AD. Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date. J Asthma Allergy. 2019 Jan 3;12:1-5. doi: 10.2147/JAA.S167973. 4: Brightling C, Kulkarni S, Lambrecht BN, Sandham D, Weiss M, Altman P. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021 Jun;68:102030. doi: 10.1016/j.pupt.2021.102030. Epub 2021 Apr 4. 149(5):1587-1589. doi: 10.1016/j.jaci.2022.03.001. Epub 2022 Mar 15. 9(1):43-56. doi: 10.1016/S2213-2600(20)30412-4. Epub 2020 Sep 24.
合成参考文献
参考文献:10.1007/s12098-018-2686-0 摘要:Maitra A. Severe Asthma: Challenges and Pitfalls in Management. Indian J Pediatr. 2018 Sep;85(9):763–72. doi: 10.1007/s12098-018-2686-0. 参考文献:10.4049/jimmunol.2001245 摘要:Chen W, Luo J, Ye Y, Hoyle R, Liu W, Borst R, Kazani S, Shikatani EA, Erpenbeck VJ, Pavord ID, Klenerman P, Sandham DA, Xue L. The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism. J Immunol. 2021 Jun 01;206(11):2714–24. 摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749